Saturday, June 10, 2023
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.
Professor of Psychopharmacology and Affective Disorders
Institute of Psychiatry, Psychology and Neuroscience
King's College London
London, United Kingdom
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
This educational activity is intended for an international audience of psychiatrists, primary care physicians, and neurologists practicing in Europe, the Middle East, and North Africa.
The goal of this activity is that learners will be better able to determine which patients with major depressive disorder (MDD) and treatment-resistant depression (TRD) may benefit from treatment that targets the glutamate receptor.
Upon completion of this activity, participants will:
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.
Professor of Psychopharmacology and Affective Disorders
Institute of Psychiatry, Psychology and Neuroscience
King's College London
London, United Kingdom
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information about your
eligibility to claim
credit, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the
time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online
during the credit
eligibility period that is noted on the title page.
Follow these steps to claim a credit certificate for completing this activity:
We encourage you to complete an Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied
in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well
as the certificates by
accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CPD Released: 5/2/2022
Valid for credit through: 5/2/2023
processing....
The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.
 |
Arnold is a 53-year-old truck driver and has major depressive disorder (MDD). He previously received treatment with 2 antidepressants and cognitive behavioral therapy (CBT). In his current depressive episode, he received citalopram, followed by sertraline, combined with CBT. Arnold is divorced, and he can no longer support his 2 children who live with his former partner. He is struggling at work and has moved from job to job over the years. Arnold has hypertension and hypercholesterolemia, both of which are controlled with medication. He also has a history of traumatic brain injury following an accident 4 years ago, and he is recovering from an addiction to prescription painkillers. He presents with ongoing symptoms of anhedonia, fatigue, depressed mood, and lack of energy.
